Spero Therapeutics (SPRO) Retained Earnings (2016 - 2026)
Spero Therapeutics posted quarterly Retained Earnings of -$458.3 million for Q1 2026, up 3.22% year-on-year from -$444.0 million in Q1 2025, and down 1.6% on a QoQ basis from -$451.1 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Retained Earnings data on file, last reported at -$458.3 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 3.22% year-over-year to -$458.3 million; the trailing twelve-month figure through Mar 2026 stood at -$458.3 million (up 3.22% YoY), and the FY2025 full-year result was -$451.1 million, up 1.86% from the prior year.
- Retained Earnings for Q1 2026 stood at -$458.3 million, down from -$451.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at -$391.1 million in Q4 2023 and bottomed at -$482.6 million in Q3 2025.
- The 5-year median for Retained Earnings is -$439.8 million (2022), against an average of -$439.6 million.
- The widest annual swing landed in 2022, when Retained Earnings slumped 35.89%; it then gained 5.48% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$440.6 million in 2022, then grew by 11.24% to -$391.1 million in 2023, then decreased by 17.53% to -$459.6 million in 2024, then increased by 1.86% to -$451.1 million in 2025, then declined by 1.6% to -$458.3 million in 2026.
- The last three Retained Earnings figures came in at -$458.3 million (Q1 2026), -$451.1 million (Q4 2025), and -$482.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | -458.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -458.27 Mn |
| Dec 31, 2025 | -451.07 Mn |
| Sep 30, 2025 | -482.60 Mn |
| Jun 30, 2025 | -475.20 Mn |
| Mar 31, 2025 | -473.50 Mn |
| Dec 31, 2024 | -459.64 Mn |
| Sep 30, 2024 | -438.75 Mn |
| Jun 30, 2024 | -421.60 Mn |
| Mar 31, 2024 | -403.70 Mn |
| Dec 31, 2023 | -391.07 Mn |
| Sep 30, 2023 | -442.26 Mn |
| Jun 30, 2023 | -439.06 Mn |
| Mar 31, 2023 | -427.10 Mn |
| Sep 30, 2022 | -440.60 Mn |
| Jun 30, 2022 | -429.00 Mn |
| Mar 31, 2022 | -400.29 Mn |
| Dec 31, 2021 | -367.46 Mn |
| Sep 30, 2021 | -338.20 Mn |
| Jun 30, 2021 | -315.70 Mn |
| Mar 31, 2021 | -297.10 Mn |
| Dec 31, 2020 | -7,000.00 |
| Sep 30, 2020 | 1,000.00 |
| Jun 30, 2020 | 15,000.00 |
| Mar 31, 2020 | -222.69 Mn |
| Dec 31, 2019 | -199.43 Mn |
| Sep 30, 2019 | 18,000.00 |
| Jun 30, 2019 | -156.72 Mn |
| Mar 31, 2019 | 1,000.00 |
| Dec 31, 2018 | -28,000.00 |
| Sep 30, 2018 | -23,000.00 |
| Jun 30, 2018 | -117.44 Mn |
| Mar 31, 2018 | -29,000.00 |
| Dec 31, 2017 | -96.84 Mn |
| Sep 30, 2017 | -82.19 Mn |
| Jun 30, 2017 | 1.00 Mn |
| Dec 31, 2016 | -45.44 Mn |